D'Antonio Francesco, Marinceu Delia, Eltaweel Nashwa, Prasad Smriti, Khalil Asma
Center for Fetal Care and High-Risk Pregnancy, University of Chieti, Chieti, Italy (D'Antonio).
Maternity Unit, The York District Hospital, York, UK (Marinceu).
Am J Obstet Gynecol MFM. 2025 May;7(5):101503. doi: 10.1016/j.ajogmf.2024.101503. Epub 2024 Oct 5.
Twin-to-twin transfusion syndrome (TTTS) is associated with excess perinatal mortality and morbidity. Even though Quintero staging is commonly used to assess its severity, the limitations of its prognostic value have been highlighted by researchers over the years. Recent literature indicates that fetal survival, whether for both twins or at least one, following fetoscopic laser photocoagulation of the placental anastomoses is similar in TTTS Quintero stages I and II (combined) and III and IV (combined). In this context we perform a systematic review and meta-analysis of the published literature to elucidate the survival rate of twins according to the stage of TTTS and to compare the survival rates in pregnancies complicated by stage I and II (combined) vs those with stages III and IV (combined).
Medline, Embase, and Cochrane databases were searched.
The inclusion criteria were studies reporting the outcome of monochorionic diamniotic (MCDA) twin pregnancies with TTTS undergoing laser therapy according to the Quintero stage of the disease. The primary outcome was double survival at birth. The secondary outcomes were no survival and survival of at least one twin. All the explored outcomes were reported according to the Quintero staging system. Furthermore, we aimed to compare all the observed outcomes in pregnancies complicated by TTTS affected by stage I and II vs those with stages III and IV.
Random-effect meta-analyses were used to combine data, and the results reported as pooled proportions or odd ratios (OR) with their 95% confidence intervals (CI).
A total of 26 studies were included. Survival of both fetuses was observed in 72.9% (95% CI 68.2-77.3) of pregnancies complicated by stage I, 67.9% (95% CI 62.3-73.3) with stage II, 48.1% (95% CI 42.5-53.8) with stage III, and 53.4% (95% CI 42.5-64.3) with stage IV TTTS. At least one survivor was reported in 89.4% (95% CI 86.9-91.9) of cases with stage I, 87.1% (95% CI 82.9-90.7) with stage II, 77.3% (95% CI 71.7-82.5) with stage III, and 80.1% (95% CI 69.4-89.0) with stage 4. The corresponding figures for no survivors were 10.7% (95% CI 7.7-14.0), 11.4% (95% CI 7.8-15.6), 20.4% (95% CI 15.6-25.8), and 16.7% (95% CI 8.3-27.2), respectively. When comparing the different outcomes according to the different TTTS stages, there was no significant difference in the incidence of double survival (P=.933), at least one survivor (P=.688), and no survivors (P=.866) between stages I and II TTTS. There was also no significant difference in the incidence of double survival (P=.201), at least one survivor (P=.380), and no survivors (P=.947) between stages III and IV. Conversely, when comparing the outcome of pregnancies with stage I/II (combined) vs stages III/IV (combined), the incidence of double survival was significantly higher in pregnancies with stages I/II (OR 2.19; 95% CI 1.9-2.6, P<.001). Likewise, the incidence of at least one survivor was significantly higher (OR 1.85, 95% CI 1.5-2.6, P<.001) while that of no survivor (OR 0.56, 95% CI 0.4-0.7, P<.001) significantly lower in pregnancies with stages I/II compared to III/IV.
Perinatal survival of MCDA twin pregnancies complicated by TTTS and treated with fetoscopic laser coagulation of placental anastomoses is not significantly different between stages I and II, or between stages III and IV, apart from a higher chance of one survivor in stage III compared to stage IV. The findings from this systematic review will be useful in individualized risk assessment of twin pregnancies complicated by TTTS and tailored counseling of the parents. It also highlights the need for studies aimed at better characterizing the prenatal risk factors for mortality in pregnancies complicated by TTTS.
Perinatal survival of MCDA twin pregnancies complicated by TTTS and treated with fetoscopic laser coagulation of placental anastomoses is not significantly different between stages I and II, or between stages III and IV. El resumen está disponible en Español al final del artículo.
双胎输血综合征(TTTS)与围产期死亡率和发病率过高相关。尽管Quintero分期常用于评估其严重程度,但多年来研究人员已强调了其预后价值的局限性。近期文献表明,在TTTS的Quintero I期和II期(合并)以及III期和IV期(合并)中,胎盘吻合术的胎儿镜激光光凝术后,双胎或至少一胎的胎儿存活率相似。在此背景下,我们对已发表的文献进行系统综述和荟萃分析,以阐明根据TTTS分期的双胎存活率,并比较I期和II期(合并)与III期和IV期(合并)的妊娠并发症的存活率。
检索了Medline、Embase和Cochrane数据库。
纳入标准为根据疾病的Quintero分期报告接受激光治疗的TTTS单绒毛膜双羊膜囊(MCDA)双胎妊娠结局的研究。主要结局是出生时双胎存活。次要结局是无存活和至少一胎存活。所有探索的结局均根据Quintero分期系统报告。此外,我们旨在比较I期和II期与III期和IV期的TTTS妊娠并发症中所有观察到的结局。
采用随机效应荟萃分析合并数据,结果报告为合并比例或比值比(OR)及其95%置信区间(CI)。
共纳入26项研究。I期妊娠并发症中72.9%(95%CI 68.2 - 77.3)观察到双胎存活,II期为67.9%(95%CI 62.3 - 73.3),III期为48.1%(95%CI 42.5 - 53.8),IV期TTTS为53.4%(95%CI 42.5 - 64.3)。I期病例中89.4%(95%CI 86.9 - 91.9)报告至少有一胎存活,II期为87.1%(95%CI 82.9 - 90.7),III期为77.3%(95%CI 71.7 - 82.5),IV期为80.1%(95%CI 69.4 - 89.0)。无存活者的相应数字分别为10.7%(95%CI 7.7 - 14.0)、11.4%(95%CI 7.8 - 15.6)、20.4%(95%CI 15.6 - 25.8)和16.7%(95%CI 8.3 - 27.2)。比较不同TTTS分期的不同结局时,I期和II期TTTS之间双胎存活(P = 0.933)、至少有一胎存活(P = 0.688)和无存活者(P = 0.866)的发生率无显著差异。III期和IV期之间双胎存活(P = 0.201)、至少有一胎存活(P = 0.380)和无存活者(P = 0.947)的发生率也无显著差异。相反,比较I/II期(合并)与III/IV期(合并)的妊娠结局时,I/II期妊娠的双胎存活发生率显著更高(OR 2.19;95%CI 1.9 - 2.6,P < 0.001)。同样,I/II期妊娠至少有一胎存活的发生率显著更高(OR 1.85,95%CI 1.5 - 2.6,P < 0.001),而无存活者的发生率(OR 0.56,95%CI 0.4 - 0.7,P < 0.001)与III/IV期相比显著更低。
除了III期比IV期有更高的一胎存活机会外,TTTS合并胎盘吻合术胎儿镜激光凝固治疗的MCDA双胎妊娠围产期存活率在I期和II期之间或III期和IV期之间无显著差异。该系统综述的结果将有助于对TTTS合并双胎妊娠进行个体化风险评估,并为父母提供针对性的咨询。它还强调了需要开展研究,以更好地确定TTTS合并妊娠中死亡的产前风险因素。
TTTS合并胎盘吻合术胎儿镜激光凝固治疗的MCDA双胎妊娠围产期存活率在I期和II期之间或III期和IV期之间无显著差异。本文末尾提供了西班牙语摘要。